Quest for the right Drug
נורמיטן 25 NORMITEN 25 (ATENOLOL)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
פומי : PER OS
צורת מינון:
טבליה : TABLETS
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Adverse reactions : תופעות לוואי
4.8 Undesirable effects Atenolol is well tolerated. In clinical studies, the undesired events reported are usually attributable to its pharmacological actions of atenolol. The following undesired events, listed by body system, have been reported with the following frequencies: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000) including isolated reports, not known (cannot be estimated from the available data). System Organ Class Frequency Undesirable Effect Blood and lymphatic system Rare Purpura, thrombocytopenia disorders Psychiatric disorders Uncommon Sleep disturbances of the type noted with other beta blockers Rare Mood changes, nightmares, confusion, psychoses and hallucinations Not known Depression Nervous system disorders Rare Dizziness, headache, paraesthesia Eye disorders Rare Dry eyes, visual disturbances Cardiac disorders Common Bradycardia Rare Heart failure deterioration, precipitation of heart block Vascular disorders Common Cold extremities Rare Postural hypotension which may be associated with syncope, intermittent claudication may be increased if already present, in susceptible patients Raynaud's phenomenon Respiratory, thoracic and Rare Bronchospasm may occur in patients mediastinal disorders with bronchial asthma or a history of asthmatic complaints Gastrointestinal disorders Common Gastrointestinal disturbances Rare Dry mouth Hepatobiliary disorders Uncommon Elevations of transaminase levels Rare Hepatic toxicity including intrahepatic cholestasis Skin and subcutaneous tissue Rare Alopecia, psoriasiform skin reactions, disorders exacerbation of psoriasis, skin rashes Not known Hypersensitivity reactions, including angioedema and urticaria Musculoskeletal and Not known Lupus like connective tissue disorders syndrome Reproductive system and Rare Impotence breast disorders General disorders and Common Fatigue administration site conditions Investigations Very rare An increase in ANA (Antinuclear Antibodies) has been observed, however the clinical relevance of this is not clear Discontinuance of the drug should be considered if, according to clinical judgement, the well-being of the patient is adversely affected by any of the above reactions. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form https://sideeffects.health.gov.il
שימוש לפי פנקס קופ''ח כללית 1994
Hypertension, angina pectoris, myocardial infarction
תאריך הכללה מקורי בסל
01/01/1995
הגבלות
תרופה שאושרה לשימוש כללי בקופ'ח
מידע נוסף